Report
Christophe-Raphaël Ganet

Vetoquinol : Fort CA T1 2020 (effet de stockage), non extrapolable

>T1 (+14%) supérieur à notre attente (achats de précaution) - Vétoquinol publie un CA T1 2020 à 103.4 M€, (+13.7% et +13.4% à tcc.) dont 53.4 M€ sur les produits Essentiels (+17.9% à tcc./ 51.6% des ventes vs 48.4% pour les produits Secondaires). Le CA des produits destinés aux Animaux de compagnie à 60.1 M€ représentent 58.1% du CA (+15,1% à tcc.) contre 43.3 M€ pour Animaux de rente (41.9% du CA) : +10.9% à tcc.Le groupe ne donne pas de guidance et précise...
Underlying
Vetoquinol SA

V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Christophe-Raphaël Ganet

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch